Hedge fund manager defends IPR petitions
igor.stevanovic / Shutterstock.com
Acorda Therapeutics, the first company to be targeted through an inter partes review (IPR) filed by US hedge fund manager Kyle Bass, has asked the US Patent and Trademark Office (USPTO) to reject the petition.
To continue reading this article and to access our full archive, digital magazines and special reports you will need a subscription.
If you have already subscribed please login.
For multi-user price options, or to check if your company has an existing subscription we can add you into, please email Atif at firstname.lastname@example.org
If you have any technical issues please email tech support.
For access to the complete website and archive choose '12 MONTH SUBSCRIPTION'. For a free, two-week trial select ‘TWO WEEK FREE TRIAL’.
Kyle Bass, Acorda Therapeutics, inter partes review, USPTO, PTAB, patents